Nuo Therapeutics Surges 29% as Narrowed Q2 Loss Confirms Aurix Device Sales Recovery

The Quick Take

• Nuo Therapeutics (AURX) jumped over 29% after reporting a significantly narrowed Q2 2026 net loss.
• Aurix wound care device sales drove the improvement, with commercial-stage momentum building.
• The micro-cap medical device stock remains pre-profitability but its trajectory is improving rapidly.

Nuo Therapeutics (ticker: AURX) surged more than 29% on Monday after the commercial-stage medical device company reported a narrowed second-quarter loss, with its Aurix bioelectric wound care device showing meaningful sales acceleration. Nuo, which develops electrical stimulation therapy for hard-to-heal wounds, has been working to scale commercial adoption following FDA clearance, and the Q2 results suggest that traction is building.

The Aurix device targets chronic wound patients, a market with significant unmet need particularly in diabetic foot ulcers and pressure injuries. Narrowing losses at this stage of commercialization typically signals that per-unit economics are becoming more favorable and that the sales infrastructure is maturing. For a micro-cap medical device company, the combination of a narrowing loss and a revenue-driven catalyst is a meaningful derisking event.

Nuo remains a speculative play with meaningful execution risk: commercial adoption of wound care devices requires sustained clinical evidence, payor coverage, and a scalable sales force. However, the Q2 data point provides a constructive short-term backdrop. Investors in this space typically watch for a revenue inflection to profitability transition within the next 4-6 quarters as the key binary event determining whether the current valuation is justified.

Synthesized from 1 source.